216 related articles for article (PubMed ID: 33649818)
1. LRPPRC contributes to the cisplatin resistance of lung cancer cells by regulating
Hu Y; Cui J; Jin L; Su Y; Zhang X
Oncol Rep; 2021 Apr; 45(4):. PubMed ID: 33649818
[TBL] [Abstract][Full Text] [Related]
2. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p.
Tian LJ; Wu YP; Wang D; Zhou ZH; Xue SB; Zhang DY; Wei YG; Liu W
Med Sci Monit; 2019 Oct; 25():8095-8104. PubMed ID: 31659146
[TBL] [Abstract][Full Text] [Related]
3. siRNA silencing EZH2 reverses cisplatin-resistance of human non-small cell lung and gastric cancer cells.
Zhou W; Wang J; Man WY; Zhang QW; Xu WG
Asian Pac J Cancer Prev; 2015; 16(6):2425-30. PubMed ID: 25824776
[TBL] [Abstract][Full Text] [Related]
4. Hesperetin reverses P‑glycoprotein‑mediated cisplatin resistance in DDP‑resistant human lung cancer cells via modulation of the nuclear factor‑κB signaling pathway.
Kong W; Ling X; Chen Y; Wu X; Zhao Z; Wang W; Wang S; Lai G; Yu Z
Int J Mol Med; 2020 Apr; 45(4):1213-1224. PubMed ID: 32124932
[TBL] [Abstract][Full Text] [Related]
5. Hypermethylation of ATP-binding cassette B1 (ABCB1) multidrug resistance 1 (MDR1) is associated with cisplatin resistance in the A549 lung adenocarcinoma cell line.
Li A; Song J; Lai Q; Liu B; Wang H; Xu Y; Feng X; Sun X; Du Z
Int J Exp Pathol; 2016 Dec; 97(6):412-421. PubMed ID: 27995666
[TBL] [Abstract][Full Text] [Related]
6. Apatinib resensitizes cisplatin-resistant non-small cell lung carcinoma A549 cell through reversing multidrug resistance and suppressing ERK signaling pathway.
Liu ZL; Jin BJ; Cheng CG; Zhang FX; Wang SW; Wang Y; Wu B
Eur Rev Med Pharmacol Sci; 2017 Dec; 21(23):5370-5377. PubMed ID: 29243778
[TBL] [Abstract][Full Text] [Related]
7. Circular RNA hsa_circ_0096157 contributes to cisplatin resistance by proliferation, cell cycle progression, and suppressing apoptosis of non-small-cell lung carcinoma cells.
Lu H; Xie X; Wang K; Chen Q; Cai S; Liu D; Luo J; Kong J
Mol Cell Biochem; 2020 Dec; 475(1-2):63-77. PubMed ID: 32767026
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of HIF-2α Reverse the Chemotherapy Resistance of Lung Adenocarcinoma A549 Cells to Cisplatin.
Gao ZJ; Yuan WD; Yuan JQ; Yuan K; Wang Y
Med Sci Monit; 2018 Feb; 24():1104-1111. PubMed ID: 29469087
[TBL] [Abstract][Full Text] [Related]
9. miR‑139‑5p enhances cisplatin sensitivity in non‑small cell lung cancer cells by inhibiting cell proliferation and promoting apoptosis via the targeting of Homeobox protein Hox‑B2.
Du H; Bao Y; Liu C; Zhong A; Niu Y; Tang X
Mol Med Rep; 2021 Feb; 23(2):. PubMed ID: 33300085
[TBL] [Abstract][Full Text] [Related]
10. Asiatic Acid (AA) Sensitizes Multidrug-Resistant Human Lung Adenocarcinoma A549/DDP Cells to Cisplatin (DDP) via Downregulation of P-Glycoprotein (MDR1) and Its Targets.
Cheng Q; Liao M; Hu H; Li H; Wu L
Cell Physiol Biochem; 2018; 47(1):279-292. PubMed ID: 29768255
[TBL] [Abstract][Full Text] [Related]
11. LncRNA-MALAT1 contributes to the cisplatin-resistance of lung cancer by upregulating MRP1 and MDR1 via STAT3 activation.
Fang Z; Chen W; Yuan Z; Liu X; Jiang H
Biomed Pharmacother; 2018 May; 101():536-542. PubMed ID: 29505924
[TBL] [Abstract][Full Text] [Related]
12. Long non‑coding RNA LUCAT1 contributes to cisplatin resistance by regulating the miR‑514a‑3p/ULK1 axis in human non‑small cell lung cancer.
Shen Q; Xu Z; Xu S
Int J Oncol; 2020 Oct; 57(4):967-979. PubMed ID: 32945379
[TBL] [Abstract][Full Text] [Related]
13. ABCB1 regulation through LRPPRC is influenced by the methylation status of the GC -100 box in its promoter.
Corrêa S; Binato R; Du Rocher B; Ferreira G; Cappelletti P; Soares-Lima S; Pinto LF; Mencalha A; Abdelhay E
Epigenetics; 2014 Aug; 9(8):1172-83. PubMed ID: 25089713
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of microRNA-196a might reverse cisplatin resistance of A549/DDP non-small-cell lung cancer cell line.
Li JH; Luo N; Zhong MZ; Xiao ZQ; Wang JX; Yao XY; Peng Y; Cao J
Tumour Biol; 2016 Feb; 37(2):2387-94. PubMed ID: 26376998
[TBL] [Abstract][Full Text] [Related]
15. Integrated analysis of DNA methylation and mRNA expression profiling reveals candidate genes associated with cisplatin resistance in non-small cell lung cancer.
Zhang YW; Zheng Y; Wang JZ; Lu XX; Wang Z; Chen LB; Guan XX; Tong JD
Epigenetics; 2014 Jun; 9(6):896-909. PubMed ID: 24699858
[TBL] [Abstract][Full Text] [Related]
16. Effects of VBMDMP on the reversal of cisplatin resistance in human lung cancer A549/DDP cells.
Wang CK; Zhang Y; Zhang ZJ; Qiu QW; Cao JG; He ZM
Oncol Rep; 2015 Jan; 33(1):372-82. PubMed ID: 25394854
[TBL] [Abstract][Full Text] [Related]
17. [Role of SOX4 on DDP Resistance in Non-small Cell Lung Cancer Cell of A549].
Li W; Liu X; Zhang G; Zhang L
Zhongguo Fei Ai Za Zhi; 2017 May; 20(5):298-302. PubMed ID: 28532536
[TBL] [Abstract][Full Text] [Related]
18. Pentraxin 3 acts as a functional effector of Akt/NF-κB signaling to modulate the progression and cisplatin-resistance in non-small cell lung cancer.
Li Y; Song X; Niu J; Ren M; Tang G; Sun Z; Kong F
Arch Biochem Biophys; 2021 Apr; 701():108818. PubMed ID: 33617838
[TBL] [Abstract][Full Text] [Related]
19. XPC inhibition rescues cisplatin resistance via the Akt/mTOR signaling pathway in A549/DDP lung adenocarcinoma cells.
Teng X; Fan XF; Li Q; Liu S; Wu DY; Wang SY; Shi Y; Dong M
Oncol Rep; 2019 Mar; 41(3):1875-1882. PubMed ID: 30628719
[TBL] [Abstract][Full Text] [Related]
20. A milbemycin compound isolated from Streptomyces Sp. FJS31-2 with cytotoxicity and reversal of cisplatin resistance activity in A549/DDP cells.
Li XQ; Yue CW; Xu WH; Lü YH; Huang YJ; Tian P; Liu T
Biomed Pharmacother; 2020 Aug; 128():110322. PubMed ID: 32505822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
